Niels E. De Vries

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Accidental tamoxifen ingestion in a two-year-old child without major immediate symptoms: Case report.

Accidental tamoxifen ingestion in a two-year-old child without major immediate symptoms: Case report.

Journal: Toxicology reports
Published: September 09, 2025

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

LC-MS/MS method development and validation for novel targeted anticancer therapies adagrasib, capmatinib, ensartinib, entrectinib, larotrectinib, lorlatinib, pralsetinib, selpercatinib and sotorasib.

Journal: Journal of pharmaceutical and biomedical analysis
Published: November 08, 2024

Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs.

Clinical Application of Volumetric Absorptive Microsampling for Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs.

Journal: Therapeutic drug monitoring
Published: June 14, 2024

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study.

Vincristine exposure in Kenyan children with cancer: CHAPATI feasibility study.

Journal: Pediatric blood & cancer
Published: February 08, 2024

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.

Journal: Therapeutic drug monitoring
Published: October 09, 2023

Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).

Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).

Journal: Die Pharmazie
Published: August 18, 2023

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development.

Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 03, 2023

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism.

Carboxylesterase 1 family knockout alters drug disposition and lipid metabolism.

Journal: Acta pharmaceutica Sinica. B
Published: April 04, 2022

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

Journal: Clinical pharmacology and therapeutics
Published: February 22, 2022

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.

Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.

Journal: Clinical pharmacology and therapeutics
Published: July 13, 2021

Topological Surface State in Epitaxial Zigzag Graphene Nanoribbons.

Topological Surface State in Epitaxial Zigzag Graphene Nanoribbons.

Journal: Nano letters
Published: April 05, 2021

Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.

Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.

Journal: Clinical pharmacology and therapeutics
Published: May 13, 2020
Showing 1-12 of 28

Last Updated: 09/26/2026